Cohort – Integrated multidisciplinary approach

https://neurodegenerationresearch.eu/survey/cohort-integrated-multidisciplinary-approach/

Title of the cohort

Cohort – Integrated multidisciplinary approach

Acronym for cohort

AMI

Name of Principal Investigator

Title Professor

First name

Last name DARTIGUES

Address of institution where award is held

Institution

Street Address

City Bordeaux Postcode 33076

Country

France

Website

www.isped.u-bordeaux2.fr

Contact email

Funding source

- 1. The cohort includes, or expects to include, incidence of the following conditions
 - Alzheimer's disease and other dementias
 - Parkinson's disease

When studies on the above condition(s) are expected to become possible

 \bullet 2011 - 2015

2a. Stated aim of the cohort

Analysis of Alzheimer disease occurrence in a rural aged population of and comparison with urban population

2b. Features distinguishing this cohort from other population cohorts

The rural origin of the selected population

3a. i) Number of publications that involve use of cohort to date

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

prevalence of dementia, prevalence of dependency, happiness, life satisfaction

3b. Publication list/link to where data or publications are accessible (if available)

3c. Information (i.e. research findings) expected to be gained from the population cohort

The main goal is to know if a routinely pesticides using is prone to Alzheimer disease

4a. Study criteria: age range of participants at recruitment

Age in years from: 65

To ('until death' if applicable): until death

4b. Study criteria: inclusion criteria

over 65 years, retired people with an agricultural work before, living in a selected rural area of Gironde

4c. Study criteria: exclusion criteria

not over 65 years, not retired people with an agricultural work before, not living in a selected rural area of Gironde

5. Size of the cohort (i.e. number of participants enrolled)

• 1,000 – 5,000 participants

6a. Measures used to characterise participants

age, gender, professional calendar (pesticides exposition), life conditions, reaction scale to life events, level of work complexity, preference scale of routinisation

6b. Additional measures for participants with a clinical disorder

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

###VALUE###

7. Study design

Prospective cohort

8. Cases matched by

- Other health assessment (specify) / N/A
- Dependency

9a. Does the study include a specialised subset of control participants

No

9b. If yes, description of specialised subset of control participants 10a. i) Data collection start date

10a. ii) Data collection end date

01-01-2012

10a iii) Data collection for this study is

- Data collection ongoing
- Closed to new patients

10b. Plans to continue the cohort study beyond the current projected end date

Yes – intend to apply for funding

11. Data collected

- Only through the study
- Through links to other records or registers (such as dental records, police records etc). Please specify
- MSA and Agrica Files

12. System in place to enable re-contact with patients for future studies

 Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database

Yes/No % available

Data summarised in database Yes

Database is web-based no

Database on spreadsheet

Database is on paper

Other (specify)

Language used:

French

13b. Format and availability of data held as individual records

Yes/No % available

Data held as individual records yes

Data is web-based

Data held on computer based records

Data held on cards

Other ((specify)
	$(OPOOH_{J})$

Language used:

French

14a. Are data available to other groups

No

15. Data sharing policy specified as a condition of use

Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups

Yes

16b. i) Description of available tissues/samples/DNA

Living donors:blood

· Living donors: blood derivatives

Living donors: DNA

16b. ii) Form available tissues/samples/DNA are supplied in

• Primary Samples: Stabilised samples (frozen or fixed)

Secondary samples: derivatives of primary samples

Secondary samples: plasma

Secondary samples: DNA

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

Yes

17. Is information on biological characteristics available to other groups

No